Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Menveo
Renata Limited
Generic: Meningococcal group A Diphtheria Conjugate Vaccine
Medicine Overview of Menveo Injection
বাংলা
English
Indication
Meningococcal infection
Administration
Administer IM only; do not administer IV, SC, or ID
Give IM injection, preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in toddlers, adolescents, and adults
Adult Dose
Meningococcal Vaccination Indicated active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in high risk adults 0.5 mL/dose IM as a single dose. Immunization for High-Risk Conditions (ACIP Guidelines) Asplenia or complement deficiencies Indicated in adults of all ages with functional asplenia or persistent complement component deficiencies Administer 2 doses at least 2 months apart to adults of all ages with functional asplenia or persistent complement component deficiencies Booster dose: Every 5 years Travel/reside in hyperendemic/epidemic countries Administer a single dose for adults who travel to or reside in countries in which...
... Show moreChild Dose
Primary Immunization (Adolescent) Routine primary vaccination of adolescents recommended at age 11 or 12 years unless high risk or outbreak requires earlier vaccination at younger age 11-12 years: 0.5 mL IM once; CDC recommends booster dose at age 16 yr 11-12 years (HIV infection): 2-dose primary series of 0.5 mL IM with at least 8 wk between doses (CDC guidelines) Catch-up schedule (Adolescent) Administer vaccine at age 13 through 18 years if not previously vaccinated If first dose is administered at age 13 through 15 years, a booster dose should be given at age 16 through 18 years; minimum interval...
... Show moreContraindication
Severe allergic reaction (e.g., anaphylaxis) after a previous dose , any component of this vaccine, or any other CRM197, diphtheria toxoid or meningococcal-containing vaccine is a contraindication to administration
Mode of Action
Presence of bacteriocidal anti-capsular meningococcal antibodies associated with protection from invasive meningococcal disease.
Meningococcal serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein carrier.
Induces production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y and W-135.
Precaution
Guillain-Barre syndrome. Preventing & managing allergic vaccine reactions. Thrombocytopenia or bleeding disorders. Immunocompromised person. Pregnancy & lactation.
Side Effect
Common solicited adverse reactions (> 10%) among children initiating vaccination at 2 months of age and receiving the four-dose series were tenderness (24-41%) and erythema at injection site (11-15%), irritability (42-57%), sleepiness (29-50%), persistent crying (21-41%), change in eating habits (17-23%), vomiting (5-11%) and diarrhea (8-16%). Common solicited adverse reactions (>10%) among children initiating vaccination at 7 months through 23 months of age and receiving the two-dose series were tenderness (10-16%) and erythema at injection site (12-15%), irritability (27-40%), sleepiness (17-29%), persistent crying (12-21%), change in eating habits (12-20%) and diarrhea (10-16%). Common solicited adverse reactions (> 10%) among children...
... Show moreInteraction
Live vaccines. Reduced immunological response w/ immunosuppresants.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register